← Product Code [PQO](/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/PQO) · K203757

# Elecsys AMH (K203757)

_Roche Diagnostics · PQO · Jun 10, 2022 · Clinical Chemistry · SESE_

**Canonical URL:** https://fda.innolitics.com/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/PQO/K203757

## Device Facts

- **Applicant:** Roche Diagnostics
- **Product Code:** [PQO](/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/PQO.md)
- **Decision Date:** Jun 10, 2022
- **Decision:** SESE
- **Submission Type:** Traditional
- **Regulation:** 21 CFR 862.1092
- **Device Class:** Class 2
- **Review Panel:** Clinical Chemistry

## Indications for Use

Elecsys AMH is intended for the in vitro quantitative determination of anti-Müllerian hormone (AMH) in human serum and lithium heparin plasma. The determination of AMH is used for the assessment of the ovarian reserve in women presenting to fertility clinics. This immunoassay is intended to distinguish between women presenting with AFC (antral follicle count) values > 15 (high ovarian reserve) and women with AFC values ≤ 15 (normal or diminished ovarian reserve). This immunoassay is intended to be used for assessing the ovarian reserve in conjunction with other clinical and laboratory findings before starting any fertility therapy. Elecsys AMH is not intended to be used for monitoring of women undergoing controlled ovarian stimulation in an Assisted Reproduction Technology program. The electrochemiluminescence immunoassay "ECLIA" is intended for use on cobas e immunoassay analyzers.

## Device Story

Elecsys AMH is an in vitro quantitative electrochemiluminescence immunoassay (ECLIA) for human serum and lithium heparin plasma; used on Roche cobas e 601 analyzers. Device measures anti-Müllerian hormone (AMH) levels to assess ovarian reserve in fertility clinic patients. Principle of operation: sandwich immunoassay using biotinylated monoclonal anti-AMH antibody and ruthenium-labeled monoclonal anti-AMH antibody. Modification includes addition of biotin scavenger antibody to R2 reagent to mitigate biotin interference up to 1200 ng/mL. Output is quantitative AMH concentration (ng/mL). Clinicians use results alongside other clinical/laboratory findings to categorize ovarian reserve (AFC > 15 vs ≤ 15) before initiating fertility therapy. Device provides standardized assessment of ovarian reserve; updated formulation improves assay robustness against biotin-containing supplements.

## Clinical Evidence

No new clinical studies were performed. Clinical performance was established in the predicate device (DEN150057). Analytical performance data provided includes precision (internal and multi-site reproducibility), linearity (0.03–23 ng/mL), and interference testing (endogenous and exogenous). Matrix comparison between serum and lithium heparin plasma showed high correlation (r=0.998).

## Technological Characteristics

Electrochemiluminescence immunoassay (ECLIA). Reagents: biotinylated monoclonal anti-AMH antibody, ruthenium-labeled monoclonal anti-AMH antibody, and biotin scavenger antibody. Measuring range: 0.03–23 ng/mL. Analyzers: cobas e 601. Standards: CLSI EP05-A3 (precision), EP17-A2 (detection limits), EP07-A3 (interference).

## Regulatory Identification

An anti-mullerian hormone test system is an in vitro diagnostic device intended to measure anti-mullerian hormone in human serum and plasma. An anti-mullerian hormone test system is intended to be used for assessing ovarian reserve in women.

## Special Controls

An anti-mullerian hormone test system must comply with the following special controls: 1) Premarket notification submissions must include the following information: i. An adequate traceability plan to minimize the risk of drift in anti-mullerian hormone test system results over time. ii. Detailed documentation of a prospective clinical study to demonstrate clinical performance or, if appropriate, results from an equivalent sample set. This detailed documentation must include the following information: a. Results must demonstrate adequate clinical performance relative to a well-accepted comparator. b. Clinical sample results must demonstrate consistency of device output throughout the device measuring range that is appropriate for the intended use population. c. Clinical study documentation must include the original study protocol (including predefined statistical analysis plan), study report documenting support for the proposed indications for use(s), and results of all statistical analyses. iii. Reference intervals generated by testing an adequate number of samples from apparently healthy normal individuals in the intended use population. 2) Your 809.10(b) compliant labeling must include a warning statement that the device is intended to be used for assessing the ovarian reserve in conjunction with other clinical and laboratory findings before starting any fertility therapy, and that the device should be used in conjunction with the Antral Follicle Count.

*Classification.* Class II (special controls). The special controls for this device are:(1) Design verification and validation must include:
(i) An adequate traceability plan to minimize the risk of drift in anti-mullerian hormone test system results over time.
(ii) Detailed documentation of a prospective clinical study to demonstrate clinical performance or, if appropriate, results from an equivalent sample set. This detailed documentation must include the following information:
(A) Results must demonstrate adequate clinical performance relative to a well-accepted comparator.
(B) Clinical sample results must demonstrate consistency of device output throughout the device measuring range that is appropriate for the intended use population.
(C) Clinical study documentation must include the original study protocol (including predefined statistical analysis plan), study report documenting support for the proposed indications for use(s), and results of all statistical analyses.
(iii) Reference intervals generated by testing an adequate number of samples from apparently healthy normal individuals in the intended use population.
(2) The labeling required under § 809.10(b) of this chapter must include a warning statement that the device is intended to be used for assessing the ovarian reserve in conjunction with other clinical and laboratory findings before starting any fertility therapy, and that the device should be used in conjunction with the antral follicle count.

## Predicate Devices

- Elecsys AMH system ([DEN150057](/device/DEN150057.md))

## Submission Summary (Full Text)

> This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com.
>
> Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/).

{0}

FDA U.S. FOOD & DRUG ADMINISTRATION

# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

ASSAY ONLY

## I Background Information:

A 510(k) Number

K203757

B Applicant

Roche Diagnostics

C Proprietary and Established Names

Elecsys AMH

D Regulatory Information

|  Product Code(s) | Classification | Regulation Section | Panel  |
| --- | --- | --- | --- |
|  PQO | Class II | 21 CFR 862.1092 - Anti-Mullerian Hormone Test System | TX - Clinical Toxicology  |

## II Submission/Device Overview:

A Purpose for Submission:

Modifications to the previously authorized Elecsys AMH (DEN150057) including changes to mitigate the risk of biotin interference.

B Measurand:

AMH (Anti-Müllerian [Mullerian] Hormone)

C Type of Test:

Quantitative Electrochemiluminescence immunoassay

Food and Drug Administration

10903 New Hampshire Avenue

Silver Spring, MD 20993-0002

www.fda.gov

{1}

K203757 - Page 2 of 9

## III Intended Use/Indications for Use:

### A Intended Use(s):

See Indications for Use below.

### B Indication(s) for Use:

Elecsys AMH is intended for the in vitro quantitative determination of anti-Müllerian hormone (AMH) in human serum and lithium heparin plasma. The determination of AMH is used for the assessment of the ovarian reserve in women presenting to fertility clinics. This immunoassay is intended to distinguish between women presenting with AFC (antral follicle count) values > 15 (high ovarian reserve) and women with AFC values ≤ 15 (normal or diminished ovarian reserve). This immunoassay is intended to be used for assessing the ovarian reserve in conjunction with other clinical and laboratory findings before starting any fertility therapy. Elecsys AMH is not intended to be used for monitoring of women undergoing controlled ovarian stimulation in an Assisted Reproduction Technology program.

The electrochemiluminescence immunoassay "ECLIA" is intended for use on cobas e immunoassay analyzers.

### C Special Conditions for Use Statement(s):

Rx - For Prescription Use Only

### D Special Instrument Requirements:

Roche cobas e 601

## IV Device/System Characteristics:

### A Device Description:

The Elecsys AMH reagent working solutions include:

- Rack Pack (kit placed on the analyzer)
- M Streptavidin-coated microparticles (transparent cap), 1 bottle, 6.5 mL: Streptavidin-coated microparticles 0.72 mg/mL; preservative.
- R1 Anti-AMH-Ab~biotin (gray cap), 1 bottle, 8 mL: Biotinylated monoclonal anti-AMH antibody (mouse) 1.0 mg/L, phosphate buffer 50 mmol/L, pH 7.5; preservative.
- R2 Anti-AMH-Ab~Ru(bpy) (black cap), 1 bottle, 8 mL: Monoclonal anti-AMH antibody (mouse) labeled with ruthenium complex 1.0 mg/L, biotin scavenger antibody 1 mg/mL, phosphate buffer 50 mmol/L, pH 7.5; preservative.

### B Principle of Operation:

The Elecsys AMH makes use of a sandwich test principle using a biotinylated monoclonal AMH-specific antibody and a monoclonal AMH-specific antibody labeled with a ruthenium complex to capture AMH present in the sample. The Elecsys AMH was updated to significantly

{2}

increase the biotin tolerance of the assay. For neutralization of free biotin in serum and plasma, an antibody, which binds specifically to free biotin and does not bind to or interact with the biotin-linker conjugates, was developed.

K203757 - Page 3 of 9

V Substantial Equivalence Information:

A Predicate Device Name(s):

Elecsys AMH system

B Predicate 510(k) Number(s):

DEN150057

C Comparison with Predicate(s):

|  Device & Predicate Device(s): | K203757 | DEN150057  |
| --- | --- | --- |
|  Device Trade Name | Elecsys AMH | Elecsys AMH system  |
|  General Device Characteristic Similarities |  |   |
|  Intended Use/Indications For Use | For the quantitative determination of anti-Mullerian hormone (AMH) levels for the assessment of ovarian reserve in women presenting to fertility clinics. | Same  |
|  Detection Method | Electrochemiluminescence | Same  |
|  Measuring Range | 0.03-23 ng/mL | Same  |
|  Sample Type/ Matrix | Human serum, lithium heparin plasma | Same  |
|  General Device Characteristic Differences |  |   |
|  Buffer composition R2 | Phosphate buffer; Anti-Biotin Antibody; specific for free, unconjugated biotin (“scavenger antibody”) | Phosphate buffer  |
|  Biotin Tolerance | Up to 1200 ng/mL | Up to 30 ng/mL  |

{3}

VI Standards/Guidance Documents Referenced:

|  Standards No. | Standards Organization | Standards Title  |
| --- | --- | --- |
|  EP05-A3 | CLSI | Evaluation of Precision of Quantitative Measurement Procedures; Approved Guideline - Third Edition  |
|  EP17-A2 | CLSI | Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures, Approved Guideline, Second Edition  |
|  EP07-A3 | CLSI | Interference Testing in Clinical Chemistry  |

VII Performance Characteristics:

A Analytical Performance:

1. Precision/Reproducibility:

Precision

An internal precision study was performed in accordance with CLSI EP05-A3, in which 5 human female serum (FS) samples, and 2 controls (C) were tested in 2 replicates per run, with 2 runs per day, for 21 days (N=84) on the cobas e 601 analyzer using 1 reagent lot. The following results were obtained:

|  Sample | Mean (ng/mL) | Repeatability (within run) |   | Intermediate Precision  |   |
| --- | --- | --- | --- | --- | --- |
|   |   |  SD | %CV | SD | %CV  |
|  FS 1 | 0.049 | 0.0008 | 1.6 | 0.001 | 2.5  |
|  FS 2 | 0.703 | 0.008 | 1.1 | 0.013 | 1.8  |
|  FS 3 | 3.77 | 0.046 | 1.2 | 0.082 | 2.2  |
|  FS 4 | 11.7 | 0.142 | 1.2 | 0.189 | 1.6  |
|  FS 5 | 21.4 | 0.327 | 1.5 | 0.451 | 2.1  |
|  C 1 | 0.907 | 0.006 | 0.7 | 0.011 | 1.2  |
|  C 2 | 4.78 | 0.041 | 0.9 | 0.061 | 1.3  |

Reproducibility

Reproducibility of the Elecsys AMH was performed at 3 sites (1 internal and 2 external) using three cobas e 601 analyzers and three reagent lots (with two reagent lots used per site). Two (2) levels of PreciControl AMH (PC) and 5 native human serum pools (HSP) were tested for 5 days, 1 run per day with 5 replicates per run. Assay calibration was performed as specified in the package insert. The results are summarized below:

K203757 - Page 4 of 9

{4}

|  Sample | Precision Type | N | Mean (ng/mL) | SD (ng/mL) (95% UCL*) | % CV (95% UCL)  |
| --- | --- | --- | --- | --- | --- |
|  HSP 1 | Total | 150 | 0.0503 | 0.00402
(0.00737) | 8.0
(14.7)  |
|   |  Reproducibility |   |   | 0.00124
(0.00139) | 2.5
(2.8)  |
|  HSP 2 | Total | 150 | 0.877 | 0.0337
(0.0526) | 3.8
(6.0)  |
|   |  Reproducibility |   |   | 0.0125
(0.0140) | 1.4
(1.6)  |
|  HSP 3 | Total | 150 | 4.57 | 0.201
(0.308) | 4.4
(6.7)  |
|   |  Reproducibility |   |   | 0.0949
(0.106) | 2.1
(2.3)  |
|  HSP 4 | Total | 150 | 13.8 | 0.662
(1.02) | 4.8
(7.4)  |
|   |  Reproducibility |   |   | 0.278
(0.312) | 2.0
(2.3)  |
|  HSP 5 | Total | 150 | 22.0 | 0.938
(1.62) | 4.3
(7.4)  |
|   |  Reproducibility |   |   | 0.272
(0.305) | 1.2
(1.4)  |
|  PC 1 | Total | 150 | 0.858 | 0.0284
(0.0428) | 3.3
(5.0)  |
|   |  Reproducibility |   |   | 0.0117
(0.0131) | 1.45
(1.5)  |
|  PC 2 | Total | 150 | 4.70 | 0.159
(0.245) | 3.4
(5.2)  |
|   |  Reproducibility |   |   | 0.0542
(0.0607) | 1.2
(1.3)  |

* UCL = Upper Confidence Level

2. Linearity/Assay Reportable Range:

Linearity

Linearity of the Elecsys AMH was evaluated using one human serum sample with high analyte content above the measuring range that was diluted to the lower end of the measuring range with an AMH-free serum for a total of 15 concentration levels across the measuring range. Samples were assayed in triplicate within a single run on one cobas e 601 analyzer, using one reagent lot. The observed values were compared to the expected values and a linear regression was performed and the deviations from linearity were acceptable.

The results support the claimed measuring range of 0.03 – 23 ng/mL.

Dilution

A dilution study was performed by diluting high concentration samples in duplicate with two different lots of Diluent Universal in 1:2 ratio. The data support the instructions for use.

K203757 - Page 5 of 9

{5}

K203757 - Page 6 of 9

3. Analytical Specificity/Interference:

## Endogenous interference

Endogenous interference was evaluated by testing 3 human female serum samples (containing low, mid, and high AMH levels) in duplicate with three reagent lots. One part of each sample was spiked with endogenous interferent (i.e., interferent pool), while the other part was spiked with the same volume of solvent (i.e., dilution pool). A series of at least 9 dilution steps was prepared by mixing the interferent pools and dilution pools. The sponsor considered a percent difference between test samples and control samples of >10% to be significant interference.

The highest concentrations of endogenous substances tested that show non-significant interference are summarized in the table below:

|  Substance | Highest concentration tested with no significant interference  |
| --- | --- |
|  Biotin | 1200 ng/mL  |
|  HAMA | 17.1 ng/mL  |
|  Hemoglobin | 1000 mg/dL  |
|  Intralipid | 1000 mg/dL  |
|  Bilirubin | 66 mg/dL  |
|  Rheumatoid Factor | 1000 IU/mL  |
|  IgG | 2.5 g/dL  |
|  IgA | 1.8 g/dL  |
|  IgM | 0.5 g/dL  |

The labeling for this device states the following:

This assay has no biotin interference in serum concentrations up to 1200 ng/mL. Pharmacokinetic studies have shown that serum concentrations of biotin can reach up to 355 ng/mL within the first hour after biotin ingestion for subjects consuming supplements of 20 mg biotin per day and up to 1160 ng/mL for subjects after a single dose of 300 mg biotin.

## Exogenous interference

Exogenous interference was evaluated by spiking pharmaceutical compounds into two human female serum sample pools (low-AMH concentration and high-AMH concentration). Samples were tested in duplicate. When concentrations were not available in the guideline, concentrations of at least three times the maximum recommended daily dose were tested. The sponsor considered a percent difference between test samples and control samples >10% to be significant interference.

The highest concentrations of exogenous substances tested that show non-significant interference are summarized in the table below:

{6}

|  Substance | Highest concentration tested with no significant interference  |
| --- | --- |
|  Acetylcysteine | 150 mg/L  |
|  Acetylsalicylic Acid | 30 mg/L  |
|  Ampicillin-Na | 75 mg/L  |
|  Ascorbic acid | 52.5 mg/L  |
|  Cefoxitin | 750 mg/L  |
|  Doxycycline | 18 mg/L  |
|  Heparin | 3300 IU/L  |
|  Levodopa | 7.5 mg/L  |
|  Methyldopa + 1.5 | 22.5 mg/L  |
|  Metronidazole | 123 mg/L  |
|  Rifampicin | 48 mg/L  |
|  Acetaminophen | 156 mg/L  |
|  Cyclosporine | 1.8 mg/L  |
|  Ibuprofen | 219 mg/L  |
|  Theophylline | 60 mg/L  |
|  Phenylbutazone | 321 mg/L  |
|  Gonapeptyl | 0.1 mg/L  |
|  Metformin | 2000 mg/L  |
|  Folic acid | 0.4 mg/L  |
|  Levothyroxine | 0.2 mg/L  |

The labeling for this device states the following limitation:

The following drugs may interfere with this test: Cetrotide, Ovitrelle, Endometrin, and Follistatin; do not use this test to analyze samples from patients who have received one or more of these products within on to two weeks of testing.

## Cross-reactivity

The cross-reactivity of the Elecsys AMH was evaluated using female serum samples with no AMH content. Samples were spiked with potential cross-reactants and measured with 1 reagent lot on 1 cobas e 601 analyzer. Samples were tested in duplicate and ≤ 0.1% cross-reactivity at 0 ng/mL AMH was observed for the following cross reactants:

|  Cross-reactant | Concentration  |
| --- | --- |
|  Activin A | 100 ng/mL  |
|  Inhibin A | 100 ng/mL  |
|  LH | 500 mIU/mL  |
|  FSH | 500 mIU/mL  |

## Hook effect

Two high concentration AMH serum samples were serially diluted using postmenopausal female serum. No hook effect was observed up to 1400 ng/mL.

## 4. Assay Reportable Range:

The claimed measuring range is from 0.03 ng/mL to 23 ng/mL.

K203757 - Page 7 of 9

{7}

K203757 - Page 8 of 9

5. Traceability, Stability, Expected Values (Controls, Calibrators, or Methods):

Traceability

The AMH CalSet are traceable to manufacturer's internal reference standards (Master Calibrators), which consist of a panel of well characterized serum reference materials covering the entire measuring range. The detailed traceability assurance plan was reviewed in DEN150057 and found to be acceptable. The target values for AMH CalSet are shown below:

|  Level | Target Value (ng/mL) | Target Range (ng/mL)  |
| --- | --- | --- |
|  Calibrator 1 | <0.1 | <0.1  |
|  Calibrator 2 | 8.0 | 7.2–8.8  |

6. Detection Limit:

The limit of blank (LoB), limit of detection (LoD), and limit of quantitation (LoQ) were determined in accordance with CLSI EP17-A2.

The LoB was defined as the 95th percentile value from N ≥ 60 measurements of analyte-free samples over several independent series and was determined to be 0.007 ng/mL.

The LoD was calculated based on the LoB and the standard deviation of low concentration samples and was determined to be 0.01 ng/mL.

The LoQ was defined as the lowest concentration of analyte that can be quantified with an intermediate precision of ≤ 20% CV and was determined to be 0.03 ng/mL.

7. Assay Cut-Off:

The AMH cutoff, intended to predict an antral follicle count (AFC) &gt;15, is 1.77 ng/mL.

B Comparison Studies:

1. Method Comparison with Predicate Device:

Two-hundred and sixty-eight (268) native human samples with AMH concentrations ranging from 0.03 – 23 ng/mL were tested using two reagent lots of the predicate assay on one cobas e 411 analyzer and three reagents lots of the updated assay on three different cobas e 601 analyzers. A small number of samples were spiked with serum containing a high level of AMH to cover the upper end of the measuring range (&gt;16 ng/mL). Results analyzed using a Passing-Bablok linear regression are shown below:

|  Slope (95% CI) | Intercept | Correlation Coefficient (r)  |
| --- | --- | --- |
|  0.959 (0.950 – 0.969) | 0.0207 | 0.973  |

{8}

K203757 - Page 9 of 9

2. **Matrix Comparison:**

The studies used to demonstrate analytical performance of the candidate device were conducted with serum samples. To demonstrate that lithium heparin plasma samples perform equivalently to serum samples, 82 matched serum and lithium heparin plasma samples covering the measuring range of the assay were tested with one reagent lot on one cobas e 601 analyzer. The results were assessed by Passing/Bablok regression analysis.

|  Slope | Intercept | Correlation Coefficient (r)  |
| --- | --- | --- |
|  1.039 | 0.011 | 0.998  |

C **Clinical Studies:**

1. **Clinical Sensitivity:**

Not applicable.

2. **Clinical Specificity:**

Not applicable.

3. **Other Clinical Supportive Data (When 1. and 2. Are Not Applicable):**

The clinical performance of the device was established in DEN150057. See section B Comparison Studies, above.

D **Clinical Cut-Off:**

The AMH cutoff, intended to predict an antral follicle count (AFC) &gt;15, was established in DEN150057 and is 1.77 ng/mL.

E **Expected Values/Reference Range:**

The expected values/reference range was established in DEN150057.

VIII **Proposed Labeling:**

The labeling supports the finding of substantial equivalence for this device.

IX **Conclusion:**

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.

---

**Source:** [https://fda.innolitics.com/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/PQO/K203757](https://fda.innolitics.com/submissions/CH/subpart-b%E2%80%94clinical-chemistry-test-systems/PQO/K203757)

**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).

**Cite:** Innolitics at https://innolitics.com